Pharmacyclics Inc

Pharmacyclics — Technical Presentation (June 2012)

19 slides from Pharmacyclics's technical presentation, Jun 19, 2012

  1. Slide 1: Combination of Ibrutinib with BR Is Active and Tolerable in R/R CLL/SLL

    Combination of the Bruton’s Tyrosine Kinase (BTK) Ua Rh Jean) KECIS2765) Giee BR Is Active and I Tolerable in P. Refractory (R/R) CLL/SLL: I im Ri I f Pha: Ib/Il rn JENNIFER R. BROWN, MD, ag Pomererid BARRIENTOS,MD?, IAN W. FLINN, MD, PHD’, PAUL BARR, \N BURGER, MD®, TASHEDA NAVARRO®, DANELLE F. AME

  2. Slide 2: Bruton's Tyrosine Kinase (BTK)

    Bruton’s Tyrosine Kinase (BTK) A critical kinase for lymphoma cell survival and proliferation BTK Is expressed and functional across non-T-cell hematopoletic lineages BTK functions downstream of a variety of receptors Essential element of B cell receptor signaling ‘Chemokine-controlled migration & a

  3. Slide 3: Ibrutinib: Inhibitor of BTK

    itor of BTK Forms a specific bond with cysteine- 481 in BTK Highly potent BTK inhibition at IC50 =0.5 nM Orally administered with once daily dosing resulting in 24-hr target inhibition No cytotoxic effect on T-cells or NK- cells LL cells promotes apoptosis and inhibits CLL cell migration and adhesio

  4. Slide 4: Study Design: PCYC-1108-CA

    Study Design: PCYC-1108-CA - Ibrutinib in combination with BR or FCR in patients with relapsed/refractory CLL” — Ibrutinib: 420 mg/day in 28-day cycles until disease progression — BR: B (70 mg/m? d1-2)/ R (375mg/m? cycle 1; 500mg/m? cycles 2-6) — administered up to 6 cycles — FCR: F (25 mg/m?d1-3)/

  5. Slide 5: Patient Eligibility

    Patient Eligibility * Diagnosis of CLL or SLL and requirement for treatment per IWCLL guidelines — 21, no more than 3 prior therapies — Adequate end-organ function — ANC 21000x10%/L _—PPlatelets = 60 x 10%/L — ALT <3x ULN Creatinine < 2 x ULN » No active/uncontrolled infection * ECOGOor1 + No malabs

  6. Slide 6: Patient Characteristics

    Patient Characteristics Age, years Median: Range: 270 years, # (%) Diagnosis, #(%) CLL SLL ECOG Performance Status, # (%) Prior Rx, #(%) Median: Range’ 3 prior regimens: Bulky Disease, #(%) = 5.0m Hgb < 11 g/dL or PLT < 100K/uL at screening Ibruti 615 41-82 7 (23) 29 (97) 1(3) 15 (50) 15 (50) 2 1-3

  7. Slide 7: Patient Characteristics (cont.)

    Patient Characteristics (cont.) Ibrutinib + BR | Ibrutinib + FCR (N=30) (N=3) # (%) 11 (7) ° (S12 month treatment free interval following purine analog regimen) Bendamustine Refractory, # (%) 4 (13) ° (S 12 month treatment free interval following bendamustine containing regimen) Prognostic Markers,

  8. Slide 8: Patient Disposition

    Patient Disposition ib+BR (N=30) Follow-Up Median (months) 84 Range 2.7-11.3 Patients Still on Study, # (%) 23 (77) Patients Discontinued, # (%) 7 (23) Primary Reasons for Discontinuation, # (%) Proceeded to SCT 5 (17) Disease Progression 2@)

  9. Slide 9: Treatment Summary

    Treatment Summary Number of Cycles of Bendamustine Received Median Range Number of Cycles of Rituximab Received Median ib % Total Planned Dose Received Median Range Subjects with Dose Modifications, # (%) Bendamustine Rituximab Ibrutinib

  10. Slide 10: Adverse Events Occurring in ≥20% of Patients

    AS OcedrInG'T in2 20% of F Patients ees of attribution) (N=30) Diarrhea 7 2 a 5 8 Insomnia 0% 20% 40% 60% 80% mmm Grade 1 mm Grade2 mm Grade3 mmm Grade 4

  11. Slide 11: Safety

    Safety Grade 3/4 hematology toxicity, # (%) Neutropenia Thrombocytopenia Grade 3/4 non-hematologic to: Rash Fatigue Tumor Lysis Syndrome Cellulitis Grade 3/4 infections, # (%) SAE, # (%) ry in >1 pt, #(%) Grade 3 Grade 4 5(17) 4(13) 3 (10) 4(13) 2(7) 3.(10) 27) 27) 2(7) 27) 4(13) ° e000

  12. Slide 12: Mean Percent Change From Baseline

    Mean Percent Change From Baseline Count That is Diminished in Combination with BR a a a g a

  13. Slide 13: Best Response

    Best Response Ibrutinib + BR (N=30) 8.1 mos median f/u #(%) cR 4 (13) PR 24 (80) sD 0 (0) PD 1)

  14. Slide 14: Best Response by Risk Features

    Best Response by Risk Features All Patients. 30 93 13 = 70 years age @ 86 29 Prior Rx, = 3 regimens 12 83 ° Hab < 11 g/dL or PLT < 100K/uL. 14 93 7 Del 11q present 13 100 15 62 Microglobulin > 3mg/L 16 94 ° Purine analog refractory " 1 ° Bendamustine refractory 4 75 ° Del 17p present va 71 14

  15. Slide 15: Ibrutinib + BR Best Response

    Ibrutinib + BR Best Response 100% gam 13% 80% i 20/30 patients have not yet reached the full 60% @EcR response assessment mmPR inclusive of bone 40% Tl Nodal marrow at least 2 months after completing BR. 20% 0% Historical BR: ORR: 59% including 9% CRs. (Fischer 2011 JCO)

  16. Slide 16: Survival Probability

    Survival Probability 28 16 5.0 78 Months on Study 10.0 125

  17. Slide 17: Limited Experience with Ibrutinib + FCR in Second Line CLL/SLL

    Limited Experience with Ibrutinib+ FCR in Second Line + Ibruti CLL/SLL + 3 patients treated, cohort closed due to limited PA- naive patients in relapsed setting + Well tolerated in 3 patients + One SAE - neutropenic fever + All 3 pts received all 6 cycles of FCR + One patient had a dose reduction +

  18. Slide 18: Summary

    Summary + Addition of ibrutinib to BR resulted in — 93% of patients achieved a IWCLL response with 13% CRs — Responses observed in BR/Purine-analog refractory patients — Low rate of disease progression + No added toxicity observed when adding ibrutinib to BR + Ibrutinib in combination with BR warran

  19. Slide 19: Acknowledgement

    Acknowledgement All the patients and their families who participated in the study Investigators and clinical research staff from all the clinical centers Pharmacyclics, Inc.

Pharmacyclics — Technical Presentation (June 2012) on 6ix